Following a tumultuous year, Emergent's founder will retire in April

Josh Sullivan

After what was almost certainly the most turbulent year in his company’s history, Fuad El-Hibri, the founder and original CEO of Emergent BioSolutions, will retire …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Following a tumultuous year, Emergent's founder will retire in April

Josh Sullivan

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

MaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host disease treatment

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

Gene editing startup Scribe Therapeutics lets go of staff as it preps for the clinic

Pfizer, GSK add risk of Guillain-Barré to RSV vaccine labels at FDA's request

Fol­low­ing a tu­mul­tuous year, Emer­gen­t's founder will re­tire in April

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Following a tumultuous year, Emergent's founder will retire in April